Biocidal activity of Ba(2+)-doped CeO(2) NPs against Streptococcus mutans and Staphylococcus aureus bacterial strains

Mishandling of antibiotics often leads to the development of multiple drug resistance (MDR) among microbes, resulting in the failure of infection treatments and putting human health at great risk. As a response, unique nanomaterials with superior bioactivity must be developed to combat bacterial infections. Herein, CeO(2)-based nanomaterials (NMs) were synthesized by employing cerium(iii) nitrate and selective alkaline ions. Moreover, the influence of alkaline ions on CeO(2) was investigated, and their characteristics, viz.: biochemical, structural, and optical properties, were altered. The size of nano Ba-doped CeO(2) (BCO) was ∼2.3 nm, relatively smaller than other NMs and the antibacterial potential of CeO(2), Mg-doped CeO(2) (MCO), Ca-doped CeO(2) (CCO), Sr-doped CeO(2) (SCO), and Ba-doped CeO(2) (BCO) NMs against Streptococcus mutans (S. mutans) and Staphylococcus aureus (S. aureus) strains was assessed. BCO outperformed all NMs in terms of antibacterial efficacy. In addition, achieving the enhanced bioactivity of BCO due to reduced particle size facilitated the easy penetration into the bacterial membrane and the presence of a sizeable interfacial surface. In this study, the minimum quantity of BCO required to achieve the complete inhibition of bacteria was determined to be 1000 μg mL(−1) and 1500 μg mL(−1) for S. mutans and S. aureus, respectively. The cytotoxicity test with L929 fibroblast cells demonstrated that BCO was less toxic to healthy cells. Furthermore, BCO did not show any toxicity and cell morphological changes in the L929 fibroblast cells, which is similar to the control cell morphology. Overall, the results suggest that nano BCO can be used in biomedical applications, which can potentially help improve human health conditions.